Tyler Starr spent the last week of his sophomore year the way most Ball State students spend their summers. Two weeks later, ...
Agios Pharmaceuticals said tebapivat fell short of expectations in a Phase 2 test in sickle cell disease. It’s the latest in ...
Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...
InvestorsHub on MSN
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO)
Stock drops after development setback Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company ...
Agios Pharmaceuticals said on Tuesday it is discontinuing development of its sickle cell disease treatment after trial ...
A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...
Agios Pharmaceuticals said on Tuesday it will stop development of its sickle cell disease treatment, sending its shares down 14% in premarket trading. The trial was designed to characterize the ...
The U.S. Food and Drug Administration is speeding up its review of an oral medicine for sickle cell disease that may fill a ...
Postoperative anemia is common after surgery and is usually temporary. For severe postoperative anemia, a blood transfusion may be necessary. Postoperative anemia is a common condition where blood ...
Aplastic anemia occurs when your bone marrow doesn’t make enough red and white blood cells, and platelets. Having fewer red blood cells causes hemoglobin to drop. Hemoglobin is the part of blood that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results